Alzamend Neuro, Inc. (ALZN) stock
ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
$1.04−0.09 (-7.96%)
Close on Nov 18, 2026Market cap $5.02MP/E –Yield –
Alzamend Neuro operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Alzamend Neuro's operating cash flow for the twelve months ending Jul 31, 2026 was -$6.84M. For fiscal 2026 it was -$8.07M. The highest annual figure on record is -$2.35M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | -$8.07M | – |
| FY2025 | Apr 30, 2025 | -$6.57M | – |
| FY2024 | Apr 30, 2024 | -$8.27M | – |
| FY2023 | Apr 30, 2023 | -$8.92M | – |
| FY2022 | Apr 30, 2022 | -$6.61M | – |
| FY2021 | Apr 30, 2021 | -$2.71M | – |
| FY2020 | Apr 30, 2020 | -$2.35M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -$1.14M | – |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -$2.80M | – |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | -$1.74M | – |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | -$1.17M | – |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | -$2.36M | – |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | -$1.06M | – |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | -$1.43M | – |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -$2.03M | – |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | -$1.51M | – |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -$3.30M | – |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -$2.24M | – |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | -$1.81M | – |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | -$2.34M | – |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | -$2.54M | – |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | -$1.56M | – |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | -$1.78M | – |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | -$2.05M | – |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | -$1.22M | – |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -$1.26M | – |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | -$806.13K | – |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | -$442.93K | – |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | -$205.10K | – |
See a number that looks wrong?